| 1 |
35121287 | The role of plasminogen activator inhibitor-1 in gynecological and obstetrical diseases: An update review. | 2022 Mar |
1 |
| 2 |
29880175 | The effects of different therapeutic modalities on cardiovascular risk factors in women with polycystıc ovary syndrome: A randomızed controlled study. | 2018 Jun |
1 |
| 3 |
27018756 | Adolescents with Classical Polycystic Ovary Syndrome Have Alterations in the Surrogate Markers of Cardiovascular Disease but Not in the Endothelial Function. The Possible Benefits of Metformin. | 2016 Oct |
1 |
| 4 |
26424816 | AMPK Inhibits the Stimulatory Effects of TGF-β on Smad2/3 Activity, Cell Migration, and Epithelial-to-Mesenchymal Transition. | 2015 Dec |
1 |
| 5 |
23981104 | Long-term effects of metformin on endothelial function in type 2 diabetes: a randomized controlled trial. | 2014 Jan |
1 |
| 6 |
23563040 | Effect of metformin on selected parameters of hemostasis in fenofibrate-treated patients with impaired glucose tolerance. | 2013 |
1 |
| 7 |
24457404 | Disparate effects of pharmacotherapy on plasma plasminogen activator inhibitor-1 levels in women with the polycystic ovary syndrome. | 2013 Oct-Dec |
3 |
| 8 |
21735693 | [Effects of metformin therapy on markers of coagulation disorders in hyperinsulinemic women with polycystic ovary syndrome]. | 2011 Apr |
1 |
| 9 |
19019358 | Endothelial function and insulin resistance in polycystic ovary syndrome: the effects of medical therapy. | 2010 Jan |
1 |
| 10 |
19414528 | Metformin decreases angiogenesis via NF-kappaB and Erk1/2/Erk5 pathways by increasing the antiangiogenic thrombospondin-1. | 2009 Aug 1 |
2 |
| 11 |
18358555 | The effect of metformin treatment on VEGF and PAI-1 levels in obese type 2 diabetic patients. | 2008 Jul |
4 |
| 12 |
17391159 | Short-term effects of metformin in type 2 diabetes. | 2007 May |
1 |
| 13 |
17587390 | Short-term effects of metformin in type 2 diabetes. | 2007 Jul |
1 |
| 14 |
16522281 | Impaired fibrinolysis and risk for cardiovascular disease in the metabolic syndrome and type 2 diabetes. | 2006 Feb |
1 |
| 15 |
16957566 | Rosiglitazone reduces microalbuminuria and blood pressure independently of glycemia in type 2 diabetes patients with microalbuminuria. | 2006 Oct |
1 |
| 16 |
17133785 | Effects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndrome. | 2006 Sep-Oct |
1 |
| 17 |
15607575 | De novo synthesis of diacylglycerol in endothelium may mediate the association between PAI-1 and the insulin resistance syndrome. | 2005 |
1 |
| 18 |
16169420 | Plasminogen activator inhibitor 1 and miscarriage after metformin treatment and laparoscopic ovarian drilling in patients with polycystic ovary syndrome. | 2005 Sep |
2 |
| 19 |
15334791 | Metabolic variations with oral antidiabetic drugs in patients with Type 2 diabetes: comparison between glimepiride and metformin. | 2004 Jun |
2 |
| 20 |
15356668 | Obesity and impaired fibrinolysis: role of adipose production of plasminogen activator inhibitor-1. | 2004 Nov |
1 |
| 21 |
12669266 | Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro. | 2003 Jan |
4 |
| 22 |
14502100 | Beneficial effects of metformin on haemostasis and vascular function in man. | 2003 Sep |
1 |
| 23 |
11953071 | [Effects of metformin on the plasminogen activator system, endocrine, metabolic profiles in patients with polycystic ovary syndrome and clomiphene resistant cases]. | 2002 Feb |
1 |
| 24 |
12202407 | Should patients with polycystic ovarian syndrome be treated with metformin? | 2002 Sep |
1 |
| 25 |
12412817 | Plasminogen activator inhibitor-1: physiologic role, regulation, and the influence of common pharmacologic agents. | 2002 Nov |
1 |
| 26 |
12453948 | Effect of combination glipizide GITS/metformin on fibrinolytic and metabolic parameters in poorly controlled type 2 diabetic subjects. | 2002 Dec |
2 |
| 27 |
11158071 | Increased PAI-1 and tPA antigen levels are reduced with metformin therapy in HIV-infected patients with fat redistribution and insulin resistance. | 2001 Feb |
4 |
| 28 |
11468878 | Digestive hemorrhage caused by a Meckel's diverticulum in a metformin-treated patient: is there any connection? | 2001 Jun |
1 |
| 29 |
10927066 | Polycystic ovary syndrome, infertility, familial thrombophilia, familial hypofibrinolysis, recurrent loss of in vitro fertilized embryos, and miscarriage. | 2000 Aug |
1 |
| 30 |
9802752 | Effect of weight change and metformin on fibrinolysis and the von Willebrand factor in obese nondiabetic subjects: the BIGPRO1 Study. Biguanides and the Prevention of the Risk of Obesity. | 1998 Nov |
2 |
| 31 |
9109854 | Metformin therapy is associated with a decrease in plasma plasminogen activator inhibitor-1, lipoprotein(a), and immunoreactive insulin levels in patients with the polycystic ovary syndrome. | 1997 Apr |
5 |
| 32 |
8879966 | Relationship between plasminogen activator inhibitor type-1 plasma levels and the lipoprotein(a) concentrations in non-insulin-dependent diabetes mellitus. | 1996 Jul |
3 |
| 33 |
7846898 | [The value of metformin in therapy of type 2 diabetes: effect on insulin resistance, diabetic control and cardiovascular risk factors]. | 1994 |
1 |
| 34 |
8387542 | Plasminogen activator inhibitor-1 synthesis in the human hepatoma cell line Hep G2. Metformin inhibits the stimulating effect of insulin. | 1993 May |
2 |
| 35 |
8462390 | Effects of metformin on insulin resistance, risk factors for cardiovascular disease, and plasminogen activator inhibitor in NIDDM subjects. A study of two ethnic groups. | 1993 Apr |
1 |
| 36 |
1285699 | [Atheroma and antithrombotic agents]. | 1992 Sep |
1 |
| 37 |
1713132 | Metformin causes a reduction in basal and post-venous occlusion plasminogen activator inhibitor-1 in type 2 diabetic patients. | 1991 May |
2 |
| 38 |
1916049 | Increased plasma plasminogen activator inhibitor 1 levels. A possible link between insulin resistance and atherothrombosis. | 1991 Jul |
1 |
| 39 |
1936471 | The effects of metformin on the fibrinolytic system in diabetic and non-diabetic subjects. | 1991 May |
1 |